^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LB1909
i
Other names: LB1909, dual specificity CD19 and CD22 CAR-T cell immunotherapy, LCAR-L10D
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Legend Biotech
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
3years
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=1, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=28 --> 1 | Trial completion date: May 2023 --> May 2021 | Recruiting --> Terminated; Suitable patients were not recruited
Clinical • Enrollment change • Trial completion date • Trial termination
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive • CD20 negative
|
LB1909
almost4years
A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1, N=28, Recruiting, Second Affiliated Hospital of Xi'an Jiaotong University | Trial primary completion date: May 2023 --> May 2021
Clinical • Trial primary completion date
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
LB1909
4years
Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=0, Withdrawn, Second Affiliated Hospital of Xi'an Jiaotong University | N=30 --> 0 | Recruiting --> Withdrawn
Clinical • Enrollment change • Trial withdrawal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
LB1909
Share via
